Key Points
T cell and Ab responses to SARS-CoV-2 persist up to 9 mo after symptoms.
SARS-CoV-2–specific CD4+ T effector and cTfh responses correlate with IgG responses.
T cell responses to SARS-CoV-2 show a high proportion of IL-2–producing CD4 T cells.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces T cell, B cell, and Ab responses that are detected for several months in recovered individuals. Whether this response resembles a typical respiratory viral infection is a matter of debate. In this study, we followed T cell and Ab responses in 24 mainly nonhospitalized human subjects who had recovered from PCR-confirmed SARS-CoV-2 infection at two time points (median of 45 and 145 d after symptom onset). Ab responses were detected in 95% of subjects, with a strong correlation between plasma and salivary anti-spike (anti-S) and anti—receptor binding domain IgG, as well as a correlation between circulating T follicular helper cells and the SARS-CoV-2–specific IgG response. T cell responses to SARS-CoV-2 peptides were determined using intracellular cytokine staining, activation markers, proliferation, and cytokine secretion. All study subjects had a T cell response to at least one SARS-CoV-2 Ag based on at least one T cell assay. CD4+ responses were largely of the Th1 phenotype, but with a lower ratio of IFN-γ– to IL-2–producing cells and a lower frequency of CD8+:CD4+ T cells than in influenza A virus (IAV)-specific memory responses within the same subjects. Analysis of secreted molecules also revealed a lower ratio of IFN-γ to IL-2 and an altered cytotoxic profile for SARS-CoV-2 S- and nucleocapsid-specific responses compared with IAV-specific responses. These data suggest that the memory T cell phenotype after a single infection with SARS-CoV-2 persists over time, with an altered cytokine and cytotoxicity profile compared with long-term memory to whole IAV within the same subjects.
Footnotes
This work was funded by Canadian Institutes of Health Research Grant VR1-172711 to T.H.W., J.L.G., J.M.R., M.A.O., A.-C.G., S.M., and A.J.M. with an additional supplement from the COVID-19 Immunity Task Force. J.L.G. received funding from an Ontario Together grant. Patient recruitment was funded by Canadian Institutes of Health Research Grant RN419944-439999 and by the Juan and Stefania Speck fund for COVID-19 and other viral infections (to M.A.O.). J.C.L. was funded by a Queen Elizabeth II/Aventis Pasteur Graduate Scholarship in Science and Technology at the University of Toronto.
The online version of this article contains supplemental material.
- Received July 21, 2021.
- Accepted November 8, 2021.
- Copyright © 2021 by The American Association of Immunologists, Inc.